Organon & (OGN) Prnewswire·2025-05-30 09:45Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that negatively impacted investors between October 31, 2024, and April 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding a significant debt reduction strategy following the acquisition of Dermavant [2] - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a dramatic decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4]